2[2]Keith MP,Gilliland WR.Updates in the management of gout.Am J Med,2007,120(3):221-224.
3[3]Davidson BL,Pasbmforoush M,Kelley WN,et al.Human hypoxanthine-guanine phospboribosyltransferase deficiency.The molecular defect in a patient with gout (HPRTAshville).J Biol Chem,1989,264(1):520-525.
4[4]Garcia-Pavia P,Tortes RJ,Rivero M,et al.Phosphoribo-sylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman.Arthritis Rheum,2003,48(7):2036-2041.
5[5]Unger S,Tausche AK,Koppraseh S,et al.Molecular basis of primary renal hyperuricemia:role of the human urate transporter hURAT1,Z Rheumatol,2007,66(7):556,558-561.
7[7]Gersch MS,Sautin YY,Gersch CM,et al.Does Tamm-Hors-fall protein-uric acid binding play a significant role in urate homeostasis? Nephrol Dial Transplant,2006,21 (10):2938-2942.
8[8]Luk A J,Simkin PA.Epidemiology of hyperuricemia and gout.Am J Manag Care,2005,11(15 Suppl):S435-442; quiz S465-468.
